Man Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Man Group’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-62,576	Closed	-$204K	–	2430
2025 Q3	$204K	Buy	+62,576	New	+$197K	﹤0.01%	2100
2022 Q4	–	Sell	-106,026	Closed	-$1.69M	–	2168
2022 Q3	$1.69M	Buy	+106,026	New	+$1.65M	0.01%	1127
2018 Q4	–	Sell	-11,258	Closed	-$277K	–	2077
2018 Q3	$277K	Buy	+11,258	New	+$244K	﹤0.01%	1971

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Man Group's RCKT Position: Q4 2025 in Review

Man Group sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 62,576 shares — an estimated $204K sold.

Man Group first reported a position in RCKT in Q3 2018 and held it in 3 quarters. The position peaked at $1.69M in Q3 2022. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

Man Group reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Man Group sold 62,576 Rocket Pharmaceuticals shares in Q4 2025, an estimated $204K.
Man Group first reported a position in Rocket Pharmaceuticals in Q3 2018 and held it in 3 quarters.
Man Group's Rocket Pharmaceuticals position peaked at $1.69M in Q3 2022.
186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on Man Group's 13F filing for Q4 2025, filed 17 Feb 2026.